Positive Outlook for NovoCure: Buy Rating Backed by Successful PANOVA-3 Trial and Promising Market Potential
H.C. Wainwright analyst Emily Bodnar has maintained their bullish stance on NVCR stock, giving a Buy rating today.Don't Miss our Black Friday ...
bovnews32m
The CYCC Conundrum: Why Cyclacel Pharmaceuticals Inc’s Stock Is Making Headlines Again
On Friday, Cyclacel Pharmaceuticals Inc (CYCC) stock saw a modest uptick, ending the day at $0.41 which represents a slight increase of $0.07 or 20.59% from the prior close of $0.34. The stock opened ...
bovnews32m
Voyager Therapeutics Inc (VYGR) Stock Dilemma: A Surge That Has Everyone Talking—What’s the Real Story?
On Friday, Voyager Therapeutics Inc (VYGR) stock saw a modest uptick, ending the day at $6.89 which represents a slight increase of $1.11 or 19.20% from the prior close of $5.78. The stock opened at ...
Novocure price target raised to $38 from $30 at H.C. Wainwright
H.C. Wainwright raised the firm’s price target on Novocure (NVCR) to $38 from $30 and keeps a Buy rating on the shares after the company ...